Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2015 - 2026)
Syndax Pharmaceuticals' (SNDX) quarterly Interest & Investment Income came in at $3.6 million in Q1 2026, down 50.42% year-on-year from $7.2 million in Q1 2025, and down 17.72% quarter-over-quarter from $4.3 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 50.42% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $12.9 million, a 34.34% decrease from a year earlier, with the FY2025 full-year figure at $22.7 million, down 12.88% from the prior year.
- Interest & Investment Income fell to $3.6 million in Q1 2026 per SNDX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $20.8 million in Q4 2023 and bottomed at -$974000.0 in Q1 2024.
- The 5-year median for Interest & Investment Income is $3.6 million (2026), against an average of $3.9 million.
- Biggest YoY gain for Interest & Investment Income was 8165.93% in 2022; the steepest drop was 8787.5% in 2022.
- Year by year, Interest & Investment Income stood at $7.5 million in 2022, then jumped by 176.68% to $20.8 million in 2023, then tumbled by 65.85% to $7.1 million in 2024, then sank by 39.11% to $4.3 million in 2025, then retreated by 17.72% to $3.6 million in 2026.
- Per Business Quant, the three latest SNDX Interest & Investment Income figures stand at $3.6 million (Q1 2026), $4.3 million (Q4 2025), and $5.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.48 Bn | 53.02 Mn | 3.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.56 Mn |
| Dec 31, 2025 | 4.33 Mn |
| Sep 30, 2025 | 5.27 Mn |
| Jun 30, 2025 | -242,000.00 |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | -61,000.00 |
| Mar 31, 2024 | -974,000.00 |
| Dec 31, 2023 | 20.81 Mn |
| Sep 30, 2023 | 5.35 Mn |
| Jun 30, 2023 | -238,000.00 |
| Mar 31, 2023 | 470,000.00 |
| Dec 31, 2022 | 7.52 Mn |
| Sep 30, 2022 | 1.78 Mn |
| Jun 30, 2022 | -695,000.00 |
| Mar 31, 2022 | -685,000.00 |
| Dec 31, 2021 | 91,000.00 |
| Sep 30, 2021 | 83,000.00 |
| Jun 30, 2021 | 8,000.00 |